Discussion of Inventors’ Path in Expert’s Obviousness Opinion Warrants Partial Exclusion in Bench Trial

Jun 15, 2022

Reading Time : 2 min

The plaintiff in this case sought to exclude an expert’s obviousness opinion on several grounds, including failure to identify specific prior art combinations, mere conclusory statements on the motivation to combine, discussion of the inventors’ path and reliance on commercial motivations. While the district court rejected all but one of these grounds, noting that the threshold for precluding expert opinions is less critical in a bench trial setting, the district court agreed that the portion of the expert opinion that addressed the inventors’ path was inadmissible.

Specifically, the expert dedicated several pages in his report to discussing the plaintiff’s internal documents and deposition testimony of the inventors, which, according to the expert, demonstrated that the inventors followed a routine and obvious procedure to select a particular salt with expected properties. The expert then concluded that this path taken by the inventors in formulating the patented compound was obvious, which therefore provided further support for his own independent determination of obviousness.

Despite the expert’s clarification that his discussion of how the inventors arrived at the invention was not necessary for his obviousness determination, the district court nevertheless excluded this portion of the opinion. In doing so, the district court adhered to the Federal Circuit’s cautionary guidance against using the inventor’s path to render an invention obvious, as this would constitute hindsight, and therefore could never lead to a conclusion of obviousness. The district court further pointed to the defendant’s failure to show that the expert’s discussion of internal documents and inventor testimony described “routine testing”—which may be permissible under particular facts—and not an inventive “trial and error procedure” used to discover new compounds. By evaluating the obviousness of the invention through the eyes of the inventor, the district court found that the expert blurred the lines between the inventors’ work and the prior art, as well as between the level of ordinary skill in the art and the inventors’ potentially exceptional skill in the art. For this reason, the district court agreed to exclude those portions of the expert opinion from the bench trial.

Practice Tip: Even in the context of a bench trial, where the exclusion of expert testimony is less critical, experts should not exclusively rely on evidence of the inventive path taken by the inventors when making an obviousness determination. Because viewing the invention with the inventor’s own blueprint fails to properly evaluate the invention in the state of the art that existed at the time, courts are likely to view such evidence as impermissible hindsight. Accordingly, to the extent experts cite evidence of the steps the inventors took to arrive at the invention, they should also include additional, independent bases for obviousness, in the event the “inventors’ path” evidence is excluded.

Exelixis, Inc. v. MSN Laboratories Private Limited et al., 1:19-cv-02017 (D. Del. Apr. 20, 2022).

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.